Recognizing Dravet Syndrome in Patients with Unexplained Epilepsy

Welcome back to another Neurology Live Peer Exchange series. In this episode titled, “Recognizing Dravet Syndrome in Patients with Unexplained Epilepsy,” expert faculty discuss the burden and heterogeneity of epilepsy and the challenges clinicians face when evaluating patients with unexplained seizures. The panel begins by reviewing the current diagnostic approach to epilepsy, including the role of patient history, neurologic examination, electroencephalography (EEG), and magnetic resonance imaging (MRI), while highlighting important differences between pediatric and adult practice settings.

The discussion explores the limitations of traditional diagnostic tools in identifying the underlying cause of epilepsy, particularly in patients with developmental delays or other atypical clinical features. Faculty emphasize that epilepsy is often a manifestation of an underlying neurologic condition rather than a disease entity itself, underscoring the importance of determining etiology whenever possible. The panel examines how advances in genetic testing have transformed the evaluation of unexplained epilepsy and developmental and epileptic encephalopathies, including Dravet syndrome.

Throughout the conversation, faculty provide insights into when clinicians should begin to suspect a genetic etiology, the clinical features that may raise concern for Dravet syndrome, and the evolving role of genetic testing in establishing a diagnosis. They also discuss the strengths and limitations of EEG, MRI, and genetic testing, including situations in which diagnostic studies may be normal despite the presence of a genetic epilepsy. Finally, the panel highlights how earlier identification of genetic causes of epilepsy can improve diagnostic accuracy and help guide future management strategies.

In the next episode, “Identifying Dravet Syndrome Earlier with Genetic Testing,” panelists will continue their discussion on Dravet syndrome and genetic epilepsies and highlight the role of genetic testing in confirming a diagnosis, guiding treatment decisions, and identifying patients who may benefit from emerging disease-modifying therapies. They also discuss the clinical importance of recognizing SCN1A-related epilepsy early to optimize long-term outcomes.